Is SIGA Technologies, Inc. overvalued or undervalued?

As of 30 June 2025, the valuation grade for SIGA Technologies, Inc. has moved from expensive to attractive, indicating a shift towards being undervalued. The company appears undervalued with a P/E ratio of 9, significantly lower than its peer Theravance Biopharma, Inc., which has a P/E of 48.04. Additionally, SIGA's EV to EBITDA ratio stands at 4.72, while its peer comparison shows a more favorable position against Theravance's negative EV to EBITDA. The company's strong ROCE of 103.73% further supports its attractiveness in the market.
In terms of returns, SIGA has shown a year-to-date return of 47.59%, outperforming the S&P 500's return of 12.22% during the same period, although it has lagged behind the index over the longer three and five-year periods. Overall, SIGA Technologies, Inc. is positioned as an attractive investment opportunity within the Pharmaceuticals & Biotechnology sector.